Long acting injectable HIV treatment offers an alternative to taking daily oral medication for eligible people living with HIV. These treatments use antiretroviral medicines administered by injection at scheduled intervals to help maintain viral suppression. Options such as cabotegravir and rilpivirine are used together for HIV treatment in specific circumstances.
Long acting injectable HIV treatment is an important development in antiretroviral therapy. Traditional HIV treatment commonly involves taking oral medication every day to suppress the virus and protect immune function. Injectable options provide another approach for eligible individuals by delivering medicines that remain active in the body over an extended period. These treatments do not cure HIV, but they can help maintain viral suppression when used according to medical guidance. Understanding the available options and their requirements helps patients make informed decisions with their healthcare providers.
Long acting injectable HIV treatment uses antiretroviral medicines formulated to remain effective between scheduled doses. One established option combines cabotegravir, an integrase strand transfer inhibitor, with rilpivirine, a non-nucleoside reverse transcriptase inhibitor. Together, these medicines target different stages of the HIV replication process.
Cabotegravir and rilpivirine injections are generally used for adults and certain adolescents who meet the applicable prescribing criteria, have maintained viral suppression on an appropriate oral HIV regimen, and have no known or suspected resistance to either medicine. Eligibility requirements can vary according to the approved product and local clinical guidance.
Important considerations include:
Cabotegravir and rilpivirine: This combination is available as long acting injectable treatment for eligible people whose HIV is already controlled.
Dosing intervals: Injections are generally administered every month or every two months, depending on the prescribed regimen and product guidance.
Oral medication transition: Some treatment plans include an oral lead in period to assess tolerability, while others allow direct transition to injections under appropriate medical supervision.
Treatment eligibility: Healthcare professionals review viral suppression, treatment history, drug resistance, other medications, and potential interactions before recommending injections.
Another important distinction is that long acting injectable cabotegravir can also be used for HIV pre exposure prophylaxis, known as PrEP, in eligible HIV negative individuals. PrEP is intended to prevent HIV infection and is different from injectable treatment for someone already living with HIV.
Long acting injectable treatment may provide practical benefits for people who find daily tablets difficult to manage. It can reduce the frequency of taking HIV medication at home and offer a more predictable treatment routine. However, it requires attendance at scheduled healthcare appointments and careful follow up.
Potential benefits and considerations include:
Reduced daily pill burden: Eligible individuals may avoid taking daily oral HIV treatment while receiving the injectable regimen.
Privacy and convenience: Some people prefer scheduled clinic visits rather than keeping or taking daily medication in settings where privacy is a concern.
Injection site reactions: Pain, swelling, redness, or tenderness can occur after injections. These reactions are commonly temporary, although severity and duration vary.
Other adverse effects: Fever, headache, fatigue, and other symptoms may occur. Serious allergic reactions and liver-related problems are possible but uncommon.
Missed appointments: Delayed injections can reduce medication coverage and increase the risk of viral rebound and drug resistance. Patients should contact their healthcare team promptly if an appointment may be missed.
Ongoing monitoring: Regular assessments help evaluate viral suppression, side effects, adherence to injection schedules, and whether the treatment remains appropriate.
If injectable treatment is discontinued, the medicines can remain in the body at declining concentrations for an extended period. A healthcare professional must arrange an appropriate alternative antiretroviral regimen to reduce the risk of developing resistance.
Long acting injectable HIV treatment is not suitable for everyone, and daily oral therapy remains an effective option for many people. Discussing individual needs, medical history, treatment preferences, and appointment availability with a qualified healthcare professional can help determine the most appropriate approach to maintaining long term HIV control.